TargetRx Atlas

MRNA basic information

  • mRNA ID:ENST00000397062
  • Gene Name:NFE2L2
  • mRNA database:Ensembl
  • mRNA expression :up-regulated
  • mRNA Method:RT–PCR
  • mRNA Pathway:Nrf2/HO-1 pathway
  • Evidence:validated
  • (mRNA-drug)

Drug basic information

  • Drug ID:DB06212
  • Drug Name:Tolvaptan
  • Drug Method:up-regulated the gene expression

Disease basic infommation

  • Disease:chronic kidney disease
  • Tissue:cell line mpkCCD

Other information

  • Title:Tolvaptan activates the Nrf2/HO-1 antioxidant pathway through PERK phosphorylation
  • Journal:Scientific Reports
  • Published:2019
  • PubMed ID:31239473
  • Abstract:Tolvaptan, a vasopressin type 2 receptor antagonist initially developed to increase free-water diuresis, has been approved for the treatment of autosomal dominant polycystic kidney disease in multiple countries. Furthermore, tolvaptan has been shown to improve the renal functions in rodent models of chronic kidney disease (CKD); however, the underlying molecular mechanisms remain unknown. CKD is characterized by increased levels of oxidative stress, and an antioxidant transcription factor-nuclear factor erythroid 2-related factor 2 (Nrf2)-has been gaining attention as a therapeutic target. Therefore, we investigated the effects of tolvaptan and a well-known Nrf2 activator, bardoxolone methyl (BARD) on Nrf2. To determine the role of tolvaptan, we used a renal cortical collecting duct (mpkCCD) cell line and mouse kidneys. Tolvaptan activated Nrf2 and increased mRNA and protein expression of antioxidant enzyme heme oxygenase-1 (HO-1) in mpkCCD cells and the outer medulla of mouse kidneys. In contrast to BARD, tolvaptan regulated the antioxidant systems via a unique mechanism. Tolvaptan activated the Nrf2/HO-1 antioxidant pathway through phosphorylation of protein kinase RNA-like endoplasmic reticulum kinase (PERK). As a result, tolvaptan and BARD could successfully generate synergistic activating effects on Nrf2/HO-1 antioxidant pathway, suggesting that this combination therapy can contribute to the treatment of CKD.
@Copyright Harbin Medical University
　The 2nd Affiliated Hospital of Harbin Medical University
　 备案号：鲁ICP备2022025566号-3